FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2791705633> ?p ?o ?g. }

• W2791705633 endingPage "292" @default.
• W2791705633 startingPage "286" @default.
• W2791705633 abstract "Absence or low anti-HBV surface antibody (anti-HBs) is associated with an increased risk of HBV reactivation in patients with lymphoma and resolved HBV infection receiving rituximab-containing chemotherapy. Quantification of anti-HBV core antibody (anti-HBc) is a new marker associated with the natural history and treatment response of chronic HBV infection. This study investigated whether baseline anti-HBc and anti-HBs levels may better predict HBV reactivation.We prospectively measured the HBV DNA levels of patients with lymphoma and resolved HBV infection receiving rituximab-cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisolone-based chemotherapy and started an antiviral therapy upon HBV reactivation, defined as a greater than 10-fold increase in HBV DNA compared with previous nadir levels. Anti-HBs and anti-HBc were quantified by a double-sandwich assay. Receiver-operating-characteristic-curve analysis was used to determine the optimal baseline anti-HBc/anti-HBs levels for predicting HBV reactivation.HBV reactivation occurred in 24 of the 197 patients enrolled, with an incidence of 11.6/100 person-years. For the 192 patients with enough serum samples for analysis, low anti-HBs (<56.48 mIU/ml) and high anti-HBc (≥6.41 IU/ml) at baseline were significantly associated with high risk of HBV reactivation (hazard ratio [HR] 8.48 and 4.52, respectively; p <0.01). The multivariate analysis indicated that (1) patients with both high anti-HBc and low anti-HBs at baseline (36 of 192 patients) had an HR of 17.29 for HBV reactivation (95% CI 3.92-76.30; p <0.001), and (2) HBV reactivation may be associated with inferior overall survival (HR 2.41; 95% CI 1.15-5.05; p = 0.02).Baseline anti-HBc/anti-HBs levels may predict HBV reactivation in these patients with lymphoma and help optimize prophylactic antiviral therapy for high-risk patients.In this study, we identified a subgroup of patients with lymphoma and resolved hepatitis B virus infection that had a high risk of hepatitis B virus reactivation after receiving rituximab-containing chemotherapy. These findings will help optimize a preventive strategy, especially in hepatitis B virus endemic regions with limited healthcare resources. Clinical trial number: NCT 00931229." @default.
• W2791705633 created "2018-03-29" @default.
• W2791705633 creator A5003451116 @default.
• W2791705633 creator A5004699298 @default.
• W2791705633 creator A5008236793 @default.
• W2791705633 creator A5019609523 @default.
• W2791705633 creator A5024315802 @default.
• W2791705633 creator A5040691782 @default.
• W2791705633 creator A5058253583 @default.
• W2791705633 creator A5066852913 @default.
• W2791705633 creator A5072134739 @default.
• W2791705633 creator A5074026718 @default.
• W2791705633 creator A5080937676 @default.
• W2791705633 creator A5086740134 @default.
• W2791705633 creator A5088393966 @default.
• W2791705633 creator A5089306362 @default.
• W2791705633 date "2018-08-01" @default.
• W2791705633 modified "2023-10-18" @default.
• W2791705633 title "Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection" @default.
• W2791705633 cites W1555292656 @default.
• W2791705633 cites W1764314633 @default.
• W2791705633 cites W1846877014 @default.
• W2791705633 cites W1969956513 @default.
• W2791705633 cites W1979792611 @default.
• W2791705633 cites W1986705681 @default.
• W2791705633 cites W1994351795 @default.
• W2791705633 cites W2025722002 @default.
• W2791705633 cites W2099753264 @default.
• W2791705633 cites W2117352205 @default.
• W2791705633 cites W2137245721 @default.
• W2791705633 cites W2139344413 @default.
• W2791705633 cites W2140505684 @default.
• W2791705633 cites W2140921924 @default.
• W2791705633 cites W2147134417 @default.
• W2791705633 cites W2151523434 @default.
• W2791705633 cites W2163147639 @default.
• W2791705633 cites W2166877704 @default.
• W2791705633 cites W2174723704 @default.
• W2791705633 cites W2336828061 @default.
• W2791705633 cites W2391257815 @default.
• W2791705633 cites W2523101013 @default.
• W2791705633 cites W2605785536 @default.
• W2791705633 doi "https://doi.org/10.1016/j.jhep.2018.02.033" @default.
• W2791705633 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29551710" @default.
• W2791705633 hasPublicationYear "2018" @default.
• W2791705633 type Work @default.
• W2791705633 sameAs 2791705633 @default.
• W2791705633 citedByCount "69" @default.
• W2791705633 countsByYear W27917056332018 @default.
• W2791705633 countsByYear W27917056332019 @default.
• W2791705633 countsByYear W27917056332020 @default.
• W2791705633 countsByYear W27917056332021 @default.
• W2791705633 countsByYear W27917056332022 @default.
• W2791705633 countsByYear W27917056332023 @default.
• W2791705633 crossrefType "journal-article" @default.
• W2791705633 hasAuthorship W2791705633A5003451116 @default.
• W2791705633 hasAuthorship W2791705633A5004699298 @default.
• W2791705633 hasAuthorship W2791705633A5008236793 @default.
• W2791705633 hasAuthorship W2791705633A5019609523 @default.
• W2791705633 hasAuthorship W2791705633A5024315802 @default.
• W2791705633 hasAuthorship W2791705633A5040691782 @default.
• W2791705633 hasAuthorship W2791705633A5058253583 @default.
• W2791705633 hasAuthorship W2791705633A5066852913 @default.
• W2791705633 hasAuthorship W2791705633A5072134739 @default.
• W2791705633 hasAuthorship W2791705633A5074026718 @default.
• W2791705633 hasAuthorship W2791705633A5080937676 @default.
• W2791705633 hasAuthorship W2791705633A5086740134 @default.
• W2791705633 hasAuthorship W2791705633A5088393966 @default.
• W2791705633 hasAuthorship W2791705633A5089306362 @default.
• W2791705633 hasConcept C120665830 @default.
• W2791705633 hasConcept C121332964 @default.
• W2791705633 hasConcept C126322002 @default.
• W2791705633 hasConcept C159047783 @default.
• W2791705633 hasConcept C159654299 @default.
• W2791705633 hasConcept C203014093 @default.
• W2791705633 hasConcept C207103383 @default.
• W2791705633 hasConcept C2522874641 @default.
• W2791705633 hasConcept C2776694085 @default.
• W2791705633 hasConcept C2776715498 @default.
• W2791705633 hasConcept C2776755627 @default.
• W2791705633 hasConcept C2777410769 @default.
• W2791705633 hasConcept C2779338263 @default.
• W2791705633 hasConcept C2779429289 @default.
• W2791705633 hasConcept C2780593183 @default.
• W2791705633 hasConcept C2780653079 @default.
• W2791705633 hasConcept C44249647 @default.
• W2791705633 hasConcept C61511704 @default.
• W2791705633 hasConcept C71924100 @default.
• W2791705633 hasConcept C90924648 @default.
• W2791705633 hasConceptScore W2791705633C120665830 @default.
• W2791705633 hasConceptScore W2791705633C121332964 @default.
• W2791705633 hasConceptScore W2791705633C126322002 @default.
• W2791705633 hasConceptScore W2791705633C159047783 @default.
• W2791705633 hasConceptScore W2791705633C159654299 @default.
• W2791705633 hasConceptScore W2791705633C203014093 @default.
• W2791705633 hasConceptScore W2791705633C207103383 @default.
• W2791705633 hasConceptScore W2791705633C2522874641 @default.
• W2791705633 hasConceptScore W2791705633C2776694085 @default.

• next